Executive interview – CytoDyn

Executive interview – CytoDyn

CytoDyn is on the cusp of potentially garnering its first FDA approval for its lead drug, Leronlimab (PRO 140) in HIV. In this video, the CEO and chief medical officer discuss how the company reached this point and what’s next, including a potentially transformative pipeline of opportunities in metastatic cancer, also now in development.


You may also be interested in these:

Consumer

BAT – H125 results highlights

Healthcare

Oryzon Genomics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free